Genesis Research: What is EVID AI?
December 14, 2021 | AI, HEOR, HTA, Market Access, RWE, artificial intelligence, evidence, health technology assessment, literature review, machine learning, real-world evidence, systematic literature review
Genesis Research Announces Significant Enhancements to EVID AI, the World’s Largest AI-Enabled Healthcare Literature Database for Faster, More Efficient Searches
Genesis Research, the leading Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) company, announces new enhancements to EVID AI, the world’s largest current healthcare literature research platform, that helps pharma teams and other healthcare decision makers find high quality, targeted results faster, more efficiently and from an unprecedented breadth of sources. Click here for a video about EVID AI.
“The published evidence base is constantly evolving and it’s critical to keep on top of it all,” says Genesis AI President Matthew Michelson. “EVID AI is the only platform with the capability to turn data embedded in multiple articles into structured tables that present relevant, requested data points in a clear format. This patented approach distils evidence into usable data, so that researchers can more easily develop graphs and dashboards to share with stakeholders without having to read a large volume of papers.”
EVID AI is the only healthcare literature database that uses machine learning to produce more than 80 million data points ─ from pre-clinical, clinical, economic, epidemiology, patient reported outcomes and review focus areas ─ and allows users to filter search results to only the most relevant, current information needed for further analysis.
Researchers can quickly retrieve only what they’re looking for ─ outcomes, survival results, safety, efficacy, healthcare utilization, costs, epidemiology, etc. ─ and avoid irrelevant articles. Pharmaceutical manufacturers, payers, governments agencies, and other healthcare decisionmakers can use this platform internally or engage a Genesis Research team for additional support.
As the demand for RWE increases, these transparent, reproducible literature searches, which clearly denote source materials, will enhance the efficiency of clinical development and commercialization programs, as well as support RWE studies that provide key insights about therapies.
Using EVID AI, certain literature-bound tasks can be done 59 times faster than manual efforts, with significantly more relevant evidence per search and 15 times fewer irrelevant articles. The patented machine-learning format, programmed through exposure to tens of thousands of training data points, is faster and more comprehensive than ever and will cut research time from months to weeks or days.
EVID AI is now being used by top pharma companies to provide end-to-end evidence that is critical for RWE, HEOR, market access, R&D, medical affairs, drug safety, epidemiology, and marketing.
- EVID AI can answer crucial questions around the epidemiology of symptoms and indications.
- The platform can create landscapes of competitive drugs and their associated outcomes such as safety and efficacy.
- Healthcare stakeholders can more efficiently and flexibly develop evidence-based arguments to government bodies and health technology assessments (HTAs).
- The comprehensive database supports both larger, structured projects, such as literature reviews, as well as smaller ad-hoc inquiries about economic and epidemiology impact models that support decision making.
For example, early in the pandemic, as data was changing quickly, a search was conducted on published COVID-19 data available to explore claims about the virus’s effect on births and the incidence of gastroenterological symptoms associated with COVID-19. Researchers found that most deliveries to women with confirmed COVID-19 were healthy, and that despite reports to the contrary, it didn’t appear that gastroenterological symptoms, especially diarrhea, were reliable for diagnosis alone, with overall incidence at less than 10%. As peer-reviewed articles about COVID-19 continue to be added to the database, EVID AI will serve as a valuable resource for retrieving updated information.
“EVID AI is a powerful tool that is already being used by some of the world’s premier pharmaceutical companies,” says Frank A. Corvino, Co-founder and CEO of Genesis Research. “Our pharma clients are excited about the enhanced capability for faster and more targeted literature searches as a standalone platform or in partnership with our client teams.”
Click here for a short explanatory video of EVID AI and for further information.
Company Details
Latest Content from Genesis Research Group
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright's HEOR Theater presentation 'MFN Pricing: More Fun to Navigate – A European Roadmap to Success,' with potentially...
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice...
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice...
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...